Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IVVD Invivyd	$0.65 -2.8%	$0.78	$0.35 ▼ $2.74	$77.96M	0.41	4.30 million shs	807,216 shs
MNPR Monopar Therapeutics	$42.71 -4.2%	$35.51	$1.72 ▼ $54.30	$261.09M	1.01	360,303 shs	16,183 shs
RNAC Cartesian Therapeutics	$11.83 -1.8%	$14.52	$8.85 ▼ $41.87	$306.48M	0.55	116,412 shs	45,578 shs
TSVT 2seventy bio	$4.98 -0.2%	$4.31	$2.29 ▼ $5.30	$260.64M	1.04	609,514 shs	261,188 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IVVD Invivyd	0.00%	+27.43%	+8.32%	+57.67%	-69.77%
MNPR Monopar Therapeutics	0.00%	+7.88%	+5.90%	+27.42%	+1,197.78%
RNAC Cartesian Therapeutics	0.00%	+12.67%	-18.64%	-39.08%	-43.75%
TSVT 2seventy bio	0.00%	0.00%	+0.61%	+96.84%	+17.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IVVD Invivyd	3.5468 of 5 stars	3.6	4.0	2.2	3.3	1.3
MNPR Monopar Therapeutics	3.0672 of 5 stars	3.4	5.0	3.3	2.5	0.0
RNAC Cartesian Therapeutics	1.9626 of 5 stars	3.4	0.0	3.3	3.3	0.0
TSVT 2seventy bio	1.6284 of 5 stars	2.1	2.0	2.0	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IVVD Invivyd	3.25	Buy	$7.52	1,056.59% Upside
MNPR Monopar Therapeutics	2.75	Moderate Buy	$55.33	29.56% Upside
RNAC Cartesian Therapeutics	2.75	Moderate Buy	$42.67	260.66% Upside
TSVT 2seventy bio	2.29	Hold	$5.60	12.45% Upside

Current Analyst Ratings Breakdown

Latest IVVD, RNAC, TSVT, and MNPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/24/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
4/9/2025	RNAC Cartesian Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$41.00 ➝ $41.00
4/9/2025	RNAC Cartesian Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
4/8/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
4/2/2025	MNPR Monopar Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
4/1/2025	MNPR Monopar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
3/26/2025	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/22/2025	TSVT 2seventy bio	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
3/20/2025	IVVD Invivyd	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
3/19/2025	MNPR Monopar Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$76.00
3/14/2025	RNAC Cartesian Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$45.00 ➝ $40.00

(Data available from 4/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IVVD Invivyd	$25.38M	3.07	N/A	N/A	$1.61 per share	0.40
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$1.88 per share	N/A
RNAC Cartesian Therapeutics	$38.91M	7.88	N/A	N/A	($82.38) per share	-0.14
TSVT 2seventy bio	$37.86M	6.88	N/A	N/A	$5.04 per share	0.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IVVD Invivyd	-$198.64M	-$1.44	N/A	5.91	N/A	N/A	-155.33%	-114.88%	5/8/2025 (Estimated)
MNPR Monopar Therapeutics	-$8.40M	-$3.60	N/A	N/A	N/A	N/A	-107.21%	-87.57%	5/8/2025 (Estimated)
RNAC Cartesian Therapeutics	-$219.71M	-$52.83	N/A	N/A	N/A	-510.72%	N/A	-6.03%	5/6/2025 (Estimated)
TSVT 2seventy bio	-$217.57M	-$1.12	N/A	N/A	N/A	-207.25%	-53.65%	-23.67%	5/1/2025 (Estimated)

Latest IVVD, RNAC, TSVT, and MNPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	N/A	RNAC Cartesian Therapeutics	-$0.61	N/A	N/A	N/A	$0.69 million	N/A
5/14/2025	Q1 2025	TSVT 2seventy bio	-$0.10	N/A	N/A	N/A	$13.96 million	N/A
5/8/2025	Q1 2025	IVVD Invivyd	-$0.04	N/A	N/A	N/A	$34.45 million	N/A
5/8/2025	N/A	MNPR Monopar Therapeutics	-$0.65	N/A	N/A	N/A	N/A	N/A
3/31/2025	Q4 2024	MNPR Monopar Therapeutics	-$0.36	-$2.23	-$1.87	-$2.23	N/A	N/A
3/25/2025	Q4 2024	TSVT 2seventy bio	-$0.23	-$0.31	-$0.08	-$0.37	$12.84 million	$2.93 million
3/20/2025	Q4 2024	IVVD Invivyd	-$0.25	-$0.15	+$0.10	-$0.15	$13.57 million	$13.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A
TSVT 2seventy bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IVVD Invivyd	N/A	1.92	1.58
MNPR Monopar Therapeutics	N/A	5.41	5.41
RNAC Cartesian Therapeutics	N/A	10.70	10.70
TSVT 2seventy bio	N/A	4.95	4.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IVVD Invivyd	70.36%
MNPR Monopar Therapeutics	1.83%
RNAC Cartesian Therapeutics	86.95%
TSVT 2seventy bio	93.90%

Insider Ownership

Company	Insider Ownership
IVVD Invivyd	25.40%
MNPR Monopar Therapeutics	34.90%
RNAC Cartesian Therapeutics	57.90%
TSVT 2seventy bio	7.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IVVD Invivyd	100	119.96 million	98.21 million	Optionable
MNPR Monopar Therapeutics	10	6.11 million	3.97 million	Not Optionable
RNAC Cartesian Therapeutics	64	25.91 million	10.70 million	Optionable
TSVT 2seventy bio	440	52.34 million	47.87 million	Optionable

IVVD, RNAC, TSVT, and MNPR Headlines

Recent News About These Companies

2seventy bio (NASDAQ:TSVT) Earns Sell (E+) Rating from Weiss Ratings

April 27 at 1:39 AM | marketbeat.com

2seventy bio (NASDAQ:TSVT) Earns "Sell (E+)" Rating from Weiss Ratings

April 26 at 1:57 AM | americanbankingnews.com

2seventy bio, Inc. (NASDAQ:TSVT) Sees Significant Drop in Short Interest

April 21, 2025 | marketbeat.com

2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT

April 16, 2025 | businesswire.com

Weiss Ratings Reiterates Sell (D-) Rating for 2seventy bio (NASDAQ:TSVT)

April 10, 2025 | marketbeat.com

2seventy bio, Inc. (NASDAQ:TSVT) Given Average Rating of "Hold" by Brokerages

April 5, 2025 | marketbeat.com

2seventy bio, Inc. (NASDAQ:TSVT) Short Interest Update

March 31, 2025 | marketbeat.com

2seventy Bio reports Q4 EPS (37c) vs ($1.11) last year

March 27, 2025 | markets.businessinsider.com

2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results

March 25, 2025 | businesswire.com

Jessica Snow Sells 2,298 Shares of 2seventy bio, Inc. (NASDAQ:TSVT) Stock

March 20, 2025 | insidertrades.com

2seventy bio, Inc. (TSVT) Upgraded to Buy: Here's Why

March 17, 2025 | zacks.com

2seventy Bio price target lowered to $5 from $6 at Morgan Stanley

March 14, 2025 | markets.businessinsider.com

2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT

March 14, 2025 | businesswire.com

2seventy bio, Inc. (NASDAQ:TSVT) Major Shareholder Sells $25,350,607.23 in Stock

March 14, 2025 | insidertrades.com

Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More

March 13, 2025 | msn.com

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of 2seventy bio, Inc. - TSVT

March 12, 2025 | prnewswire.com

Shareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public Shareholders

March 11, 2025 | businesswire.com

2seventy bio accepts Bristol Myers’ takeover bid

March 11, 2025 | thepharmaletter.com

Biotech Stock 2seventy bio, Inc. (Nasdaq: TSVT) Soars on Acquisition News

March 11, 2025 | investorideas.com

TSVT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of 2seventy bio, Inc. Is Fair to Shareholders

March 11, 2025 | tmcnet.com

2seventy Bio to be acquired by Bristol Myers for $5.00 per share in cash

March 11, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVVD, RNAC, TSVT, and MNPR Company Descriptions

Invivyd NASDAQ:IVVD

$0.65 -0.02 (-2.77%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$0.66 +0.01 (+1.40%)

As of 04/25/2025 08:00 PM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Monopar Therapeutics NASDAQ:MNPR

$42.71 -1.86 (-4.17%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$42.92 +0.21 (+0.49%)

As of 04/25/2025 06:31 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Cartesian Therapeutics NASDAQ:RNAC

$11.83 -0.22 (-1.83%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$11.79 -0.04 (-0.34%)

As of 04/25/2025 04:05 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

2seventy bio NASDAQ:TSVT

$4.98 -0.01 (-0.20%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$4.98 0.00 (0.00%)

As of 04/25/2025 05:59 PM Eastern

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time